A 2017 law designed to help lower the cost of hearing aids mandated that federal officials set rules for a new class of devices consumers could buy without needing to see an audiologist. But those regulations are still on hold.
State health officials say the federal government will likely reject any work or community engagement requirements, which were key to Republican lawmakers agreeing to extend the program that insures 100,000 low-income Montana adults.
The Medicare rule, designed by the Trump administration to take money away from drug industry brokers and provide refunds to patients, has not been implemented. But budget analysts say if it were, it would cost the government money. So senators are pushing the rule aside and claiming to save billions of dollars, which they want to use instead on new projects.
A Trump administration rule mandating that hospitals disclose true prices on their websites took effect this year. But compliance is spotty and even when the data is public, it’s hard to find and understand.
The Biden administration is moving to undo many of the changes the Trump administration made to the enrollment process for the Affordable Care Act to encourage more people to sign up for health insurance. Meanwhile, Congress is opening investigations into the controversial approval by the Food and Drug Administration of an expensive drug that might (or might not) slow the progression of Alzheimer’s disease. Joanne Kenen of Politico, Kimberly Leonard of Insider and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Marshall Allen of ProPublica about his new book, “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”
The Biden administration has started to speed efforts to reverse health policies forged under Donald Trump. Most recently, the administration overturned a ban on fetal tissue research and canceled a last-minute extension of a Medicaid waiver for Texas. That latter move may delay the Senate confirmation of President Joe Biden’s nominee to head the Medicare and Medicaid programs, as Sen. John Cornyn (R-Texas) seeks to fight back. Anna Edney of Bloomberg News, Rachel Cohrs of Stat and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
A misguided federal program called the Unapproved Drugs Initiative, which put the FDA’s stamp of approval on old drugs, led to higher prices. It’s scrapped. So now what?
A misguided federal program called the Unapproved Drugs Initiative, which put the FDA’s stamp of approval on old drugs, led to higher prices. It’s scrapped. So now what?
Return to pre-Trump policy is second win of the week for abortion-rights backers.
Dr. Robert Redfield, Trump’s CDC director, lends his scientific credibility to its Clean Air Systems subsidiary, which touts a “virus-killing ion technology” added to its fans. But indoor air quality experts question whether some of its technology works in the real world.